During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a high dose of chemotherapy, the bone marrow is received by patient the donor through infusion, which helps with resumption of blood cells production. Graft versus host disease occurs when particular type of white blood cells are not compatible with the existing cell type and thus, leads to an attack by the transplanted cells on the recipient body. It is a difficult procedure to diagnose the agents and the compatibility during the transplant. Symptoms of Gvhd are usually not too severe, though in some cases it can be fatal. During autologous transplant, the patient is free from such complications. Also, prior to the transplant, cells of the donor and recipient are closely screened and matched so as to avoid Gvhd by ensuring the closest possible match.
Graft Versus Host Disease Market Taxonomy:
By Disease Type
By Product Type
High investment in research and development is expected to favor growth of the graft versus host disease market:
In the recent past, the graft versus host disease market has significantly evolved with the introduction of biological and patented small molecule immunosuppressive therapies and been added to the treatment regime. The current research and development programs in Gvhd are equipped with novel therapies such as Adienne Pharma’s Begedina and mesenchymal stem cell therapies. R&D strategies in Gvhd are characterized by an increasing trend towards maintaining appropriate prophylactic regimens and inhibiting proliferation and activation of T-cell. Such regimens in Gvhd are tailored to conditioning and transplant type and used for hematopoietic stem cell transplantation (HSCT). However, there is significant possibility of risk of opportunistic infection during this process.
However, most of the ventures in research and development process, including academically running clinical studies regarding targeting niche subgroup under Gvhd such as steroid refractory aGVHD and cGVHD, are key R&D strategies in the GVHD pipeline, with around 30 products in the pipeline targeting such populations. Extensive research and development activities are expected to favor growth of the graft versus host disease industry in the near future.
Large unmet needs in the Gvhd management are one of the most important factors fueling growth of the graft versus host disease market. At present there are very few or no guidelines for management of graft versus host disease that can precisely maintain the data for the large population suffering from Gvhd, though certain recommendations for such therapies are in place.
Lack of regulatory guidelines pegs back growth of graft versus host disease market
The disease is orphan in nature, which can be one of the important factors affecting the lack of guidelines and treatment regimes. Lack of randomized clinical trials is another factor that contributes towards non-popularity of Gvhd due to the use of variable clinical trial endpoints conducted studies till date. This has resulted in inappropriate clinical evidences, which are not comparable and not directly applicable to all Gvhd patient groups. However, advancements in the process of early detection of symptoms is projected to support growth of the graft versus host disease market in the near future.
Major research universities in the GvHD market are engaged in research and development processes to further enhance the outcomes of the therapy. For instance, research conducted by the University Of Michigan, in 2017, revised the understanding regarding the graft vs. host disease origins, which can offer new direction for potential therapy in the near future.
Market players in the GvHD market focusing on inorganic growth strategies to strength product portfolio
The global graft versus host disease market is competitive and fragmented. Major players in the market are developing novel products and spending significantly in research and development, along with major acquisitions and collaborations to achieve competitive edge over their counterparts. For instance, Kalytera Therapeutics, Inc. acquired Talent Biotechs Ltd. – an Israeli-based developer of proprietary cannabidiol therapeutic. This is expected to favor the increase in company’s product portfolio. Some of the key players in the Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.